TriSalus Life Sciences, Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2026, TriSalus Life Sciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). A total of 41,728,676 shares of our Common Stock, or 67.9% of the total outstanding shares, of our Common Stock were represented at the Meeting. The final voting results for each of the matters submitted to a stockholder vote at the Meeting are set forth below: 1. The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows: Nominee For Withhold Broker Non-Votes ──────────────────────────────────────────────────────────────────── Mary Szela 31,393,310 2,614,246 7,721,120 Gary Gordon 31,339,161 2,668,395 7,721,120 2. The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote: For Against Abstain ──────────────────────────────────────── 41,098,385 28,667 601,624 3. The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote: 1 Year 2 Years 3 Years Abstain Broker Non-Votes ────────────────────────────────────────────────────────────────────────────── 12,656,430 736,931 20,348,386 265,809 7,721,120 After considering the results of the advisory vote, the Board of Directors approved a resolution that the Company will hold future stockholder advisory votes on named executive officer compensation every three years. 4. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers was approved by the stockholder vote: For Against Abstain Broker Non-Votes ──────────────────────────────────────────────────────────────── 32,625,082 1,206,105 176,369 7,721,120